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Abstract Purpose: P-glycoprotein (Pgp) is a transmem-
brane drug eux pump that is expressed in multidrug-
resistant cancer cells and in a variety of normal tissues,
including brain capillary endothelial cells which com-
prise the blood-brain barrier. We studied the eects of
the Pgp inhibitor, cyclosporin A (CsA), on the cere-
brospinal fluid (CSF) penetration of the Pgp substrate,
doxorubicin, in non-human primates. Methods: The
animals received doxorubicin alone (2.0 mg/kg i.v. over
60 min) or doxorubicin (1 mg/kg i.v. over 60 min) and
CsA (loading dose 4.0 mg/kg i.v. over 2 h, followed by
continuous infusion of 12 mg/kg per day over 48 h).
Plasma and CSF were collected over 48 h and the dox-
orubicin concentration was measured by reverse-phase
high-pressure liquid chromatography (HPLC) with
fluorescence detection (detection limit 5 nM). A two-
compartment model was fitted to the plasma concen-
tration-time data. Results: Pgp was demonstrated to be
present in the epithelium of the choroid plexus by
immunohistochemical methods, indicating that CSF
drug penetration could be used as a surrogate for blood-
brain barrier penetration. Steady state whole blood CsA
concentrations, which were measured with a fluores-
cence-polarization immunoassay (TDX) that detects
both CsA and its metabolites, ranged from 551–1315 lg/
l at 24 h. The clearance of doxorubicin in four animals
was reduced by 34%, 38%, 45% and 49% when given
with CsA. The doxorubicin concentration in the CSF
was <5 nM in all animals, both after doxorubicin alone
and doxorubicin with CsA. Conclusions: The Pgp in-
hibitor, CsA, at a concentration that alters systemic
clearance of doxorubicin, does not appear to signifi-
cantly increase the CSF penetration of doxorubicin.
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Introduction
The entry of drugs into the central nervous system
(CNS) is restricted by the blood-brain barrier (BBB)
which maintains the homeostasis of the central nervous
system by controlling the passage of a variety of chem-
icals into and out of the brain [1]. Anatomically, the
BBB comprises a single layer of specialized capillary
endothelial cells that are linked by tight junctions and
lack fenestrations, thereby forming a continuous physi-
cal barrier between the brain and circulating blood [2].
Brain capillary endothelial cells are also equipped
with transporters, such as P-glycoprotein (Pgp), which
are not typically found on capillary endothelial cells in
other parts of the body. Pgp is a drug eux pump that is
present on the luminal surface of brain capillary endo-
thelial cells [3, 4]. It appears to play an important role in
excluding xenobiotics, including a variety of anticancer
drugs, from the CNS [5–8]. In Pgp-deficient mdr1a
knockout mice, brain concentrations of the Pgp sub-
strate, vinblastine, are 22-fold higher than in wild-type
mice [9].
Overexpression of Pgp on the surface of cancer cells
contributes to the multidrug resistance phenotype. A
variety of drugs that inhibit Pgp are currently under-
going preclinical and clinical testing as modulators of
multidrug resistance [8, 10, 11]. Cyclosporin A (CsA) is a
potent chemosensitizing agent. CsA concentrations of 1
to 5 lg/ml modulate Pgp in vitro [12, 13], and clinical
trials utilizing CsA in combination with chemotherapy
have been performed [14–17]. In animal models and in
the clinical trials, Pgp modulation with CsA decreases
the clearance of anticancer drugs that are Pgp substrates
and enhances their toxicity, presumably by inhibition of
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Pgp-dependent drug elimination pathways in normal
liver [18].
Because Pgp-modulating agents used to reverse the
multidrug resistance phenotype in cancers can also in-
hibit Pgp expressed in normal tissues, we studied the
eect of CsA on the penetration of the Pgp substrate,
doxorubicin, into the cerebrospinal fluid (CSF) using a
non-human primate model. Enhanced CNS penetration
of anticancer drugs could be beneficial in the treatment
of primary and metastatic brain tumors, but it could
also enhance the neurotoxicity of the anticancer drug.
Therefore, it is important to study the impact of Pgp-
modulating agents on the CNS pharmacology of
anticancer drugs that are Pgp substrates.
Materials and methods
Immunohistochemistry
CSF drug penetration was used as a surrogate for BBB penetration
in the non-human primate model. Therefore, we studied the
expression of Pgp on the epithelial surface of the choroid plexus
and in brain capillary endothelial cells in the brains from two non-
human primates (Macaca mulatta) that were killed for other
reasons, in order to demonstrate that Pgp was also a component of
the blood-CSF barrier. Sections were cut at 5 lm from formalin-
fixed, paran-embedded tissue. Immunohistochemistry was
performed according to the avidin-biotin peroxidase complex
method using an ELITE Vectastain kit (Vector Laboratories,
Burlingame, Calif.) with biotinylated antimouse immunoglobulin.
The monoclonal antibodies employed were C219 (Centocor Diag-
nostics, Malvern, Pa,) and JSB-1 (Caltag, Burlingame, Calif.), both
of which recognize dierent intracytoplasmic epitopes of human
Pgp, and an unconjugated, purified mouse IgG1 (Caltag) a negative
control. All monoclonal antibodies were diluted in phosphate-
buered saline and 0.1% bovine serum albumin to a final
concentration of 10 lg/ml. The secondary antiserum was biotin-
ylated goat antimouse antiserum used at a dilution of 1/200 for 1 h.
Animal model
This study was approved by the NIH Animal Care and Use
Committee. Four adult rhesus monkeys (Macaca mulatta) ranging
in weight from 7.1 kg to 12.7 kg were used in the pharmacokinetic
studies. The animals were group-housed in accordance with the
Guide for Care and Use of Laboratory Animals [19] and received
water and Purina Monkey Chow ad libitum. Each animal had a 4th
ventricular Pudenz catheter attached to an Ommaya reservoir for
CSF sampling as previously described [20]. Blood samples were
drawn through a catheter placed in the saphenous or femoral vein
contralateral to the site of drug administration.
Each animal received doxorubicin (Rubex, Chiron Therapeu-
tics, Emeryville, Calif.) alone at a dose of 2.0 mg/kg i.v. over
60 min (equivalent to a dose of 40 mg/m2 in humans), or doxoru-
bicin at 1.0 mg/kg i.v. over 60 min and CsA (Sigma Chemical
Company, St. Louis, Mo.) administered as a loading dose of
4.0 mg/kg i.v. over 2 h followed by continuous infusion of 12 mg/
kg per day for 48 h. The dose of doxorubicin was reduced when
administered with CsA to account for the reduced clearance of
doxorubicin in the presence of Pgp inhibitors. The study followed a
crossover design and the order of administration (doxorubicin
alone vs the combination of doxorubicin and CsA) was randomly
determined.
Plasma samples were collected prior to infusion of doxorubicin,
30 min after the start of infusion, at the end of infusion, and 5, 10,
15, 30, 60, and 90 min and 2, 3, 4, 6, 8, 10, 24 and 48 h after the end
of the infusion. CSF samples were collected prior to infusion,
30 min after the start of infusion, at the end of infusion, and 0.5, 1,
1.5, 2, 3, 4, 6, 8, 10, 24 and 48 h after the end of infusion. Plasma
and CSF were frozen at )70°C until analysis. Blood samples were
also drawn for quantification of CsA plasma concentration at
steady-state (24 h).
Doxorubicin analysis
Doxorubicin concentration in plasma and CSF was measured using
an isocratic reverse-phase HPLC method with fluorescence detec-
tion. Samples were spiked with 200 nM daunorubicin (Sigma
Chemical Co., St. Louis, Mo.) as an internal standard. Plasma
samples and doxorubicin plasma standards were prepared by solid-
phase extraction. Varian Bond Elut 3 ml C18 solid-phase extraction
cartridges (Varian, Harbor City, Calif.) were wetted with 1 ml
methanol and washed with 1 ml distilled deionized water prior to
application of the plasma standard or sample. After the plasma
standard or sample had been applied to the cartridge, it was washed
with 0.5 ml distilled deionized water and the doxorubicin was
eluted with 1 ml of 9:1 methanol/formic acid ´2. The cartridge
eluant was evaporated to dryness under a stream of nitrogen and
reconstituted in 100 ll of the HPLC mobile phase. CSF samples
were extracted with 5% perchloric acid.
Extracted standards and samples were injected onto a lBond-
apak phenyl column (Waters Corporation, Milford, Mass.) with a
PS-GU phenyl 5 lm guard column (Thomson Instrument Com-
pany, Springfield, Va.). The mobile phase consisted of 79:21 (vol:
vol) 0.4 M ammonium formate/acetonitrile, pH 4.0, at a flow rate
of 2 ml/min. The HPLC system consisted of a Waters WISP 712
automated sampler, a Waters 510 pump and a Waters 470 scanning
fluorescence detector set at an excitation wavelength of 480 nm and
an emission wavelength of 595 nm. Analysis of the chromatograms
was performed with Millenium software (Waters). The limit of
detection was 5 nM, the limit of quantification was 10 nM, and the
coecient of variation was £10%.
Cyclosporin A
Steady-state CsA concentrations in whole blood were measured by
a commercial laboratory (SmithKline-Beecham, Owings Mills,
Md.) using a fluorescence-polarization immunoassay (TDX) that
detects both CsA and its metabolites.
Pharmacokinetic analysis
A two-compartment model, described by the following equations,
was fitted to the plasma concentration-time data using the mathe-
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where Cc is the concentration of drug in the central compartment at
time t;Xp is the amount of drug in the peripheral compartment; k0 is
the drug infusion rate; Vc is the volume of the central compartment;
kcel is the elimination rate constant; and kcp, kpc are the rate con-
stants for exchange of drug between the central and peripheral
compartments. AUC was determined from the model parameters
using the area under the fitted concentration-time curve. The degree




where AUCCSF is the area under the CSF concentration-time
curve, and AUCplasma is the area under the plasma concentration-
time curve.
Results
Pgp was present on the epithelial cells of the choroid
plexus and the endothelial cells of blood vessels in the
brain by immunohistochemical staining using the
monoclonal antibodies C219 and JSB-1 (Fig. 1). No
staining for Pgp was observed in the neurons or glial
cells in the brain, consistent with the findings of previous
studies [21]. No staining was observed in the endothelial
cells of blood vessels in the colon, although the epithelial
cells lining the colon did stain positive (not shown). The
isotypic monoclonal antibody that was used as a nega-
tive control did not stain the cells of the choroid plexus.
C219 stained primarily along the membrane, but also
had some cytoplasmic staining, whereas staining with
JSB-1 was primarily intracytoplasmic.
Doxorubicin disposition in the non-human primates
was similar to that observed in humans. As shown in
Fig. 2, there was an initial rapid decline in plasma
concentrations during the distributive phase (mean
t1/2a, 3 min) followed by a more prolonged elimination
phase (mean t1/2b, 12 h). Pharmacokinetic model pa-
rameters from fitting the two-compartment model to
the doxorubicin plasma concentration-time data for
individual animals with and without CsA are shown in
Table 1, and the standard pharmacokinetic parameters
derived from the model parameters are shown in
Table 2. The clearance of doxorubicin was reduced by
a mean of 42% when doxorubicin was administered in
combination with CsA, and as a result, the plasma
drug exposure from doxorubicin alone at a dose of
2 mg/kg was equivalent to the exposure achieved with
a doxorubicin dose of 1 mg/kg in combination with
CsA (Fig. 2).
Fig. 1A–I Immunohistochemical stains demonstrating the pres-
ence of P-gp on brain capillary endothelial cells that make up the
BBB and the epithelial surface of the choroid plexus. The
monoclonal antibodies, C219 and JSB-1, which are directed to
human P-gp epitopes, were used. Brown staining reveals presence
of antigen (Pgp). A Cerebrum (original magnification ´775) with
control antibody. B Cerebrum (original magnification ´350) with
JSB-1 antibody showing capillary endothelial cell staining.
C Cerebrum (original magnification ´1000) with C219 antibody
showing capillary endothelial cell staining. D Choroid plexus
(original magnification ´400) with control antibody. E Choroid
plexus (original magnification ´400) with JSB-1 antibody showing
ependymal epithelial cell staining. F Choroid plexus (original
magnification ´400) with C219 antibody showing ependymal
epithelial cell staining. G Choroid plexus (original magnification
´1150) with control antibody. H Choroid plexus (original magnifi-
cation ´1050) with JSB-1 antibody showing ependymal epithelial cell
staining. I Choroid plexus (original magnification ´1050) with C219
antibody showing ependymal epithelial cell staining
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CsA whole blood steady-state concentrations in the
four animals are shown in Table 3. There was no ap-
parent relationship between CsA blood levels and the
degree of reduction in doxorubicin clearance. There was
no increase in hematologic, hepatic, renal or neurologic
toxicity in animals receiving doxorubicin in combination
with CsA at these doses as assessed by white blood cell
nadir, serum bilirubin levels, serum creatinine levels and
close observation.
The doxorubicin concentration in the CSF was below
the limit of detection of the assay (i.e. <5 nM) in all
four animals when doxorubicin was administered alone
and in combination with CsA. The CSF penetration of
doxorubicin was <5% in the absence and presence of
CsA. The major doxorubicin metabolite, doxorubicinol,
was also not detected in the CSF.
Discussion
In non-human primates, we detected Pgp in brain cap-
illary endothelial cells and the epithelial cells of the
choroid plexus using two monoclonal antibodies di-
rected against dierent intracytoplasmic epitopes of
human Pgp. C219 is an IgG2a j monoclonal antibody
that recognizes intracytoplasmic epitopes in the region
of the nucleotide binding domain found in both the
mdr-1 and mdr-3 gene products [3, 22], and JSB-1 is an
IgG1 monoclonal antibody that detects a separate
highly conserved epitope of Pgp [23]. Immunohisto-
Fig. 2 Plasma concentration-time profile of doxorubicin in non-
human primates administered alone (s) at a dose of 2 mg/kg i.v.
over 1 h and in combination with CsA (h) at a dose of 1 mg/kg i.v.
over 1 h. CsA was administered by continuous infusion (12 mg/kg
per day) over 48 h. Points represent the mean from four animals
and the lines represent the mean model fit to the concentration-time
data using a two-compartment model
Table 3 Relationship between steady-state CsA concentration in
blood and the reduction in the clearance of doxorubicin when
doxorubicin was administered in combination with CsA
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Table 1 Pharmacokinetic model parameters (two-compartment
model) for doxorubicin in four non-human primates that received
doxorubicin (2 mg/kg i.v. over 60 min) alone ()CsA) and doxor-
ubicin (2 mg/kg i.v. over 60 min) with CsA administered by con-
tinuous infusion over 48 h (+CsA)




)CsA +CsA )CsA +CsA )CsA +CsA )CsA +CsA
R895 1.8 1.6 11.1 8.2 4.9 3.8 0.12 0.14
D16 2.7 1.4 5.3 6.4 4.1 3.7 0.09 0.09
B9078 1.5 1.1 10.8 7.8 6.2 7.6 0.09 0.08
R838 A 1.8 1.2 8.5 6.2 3.9 6.5 0.08 0.11
Mean 2.0 1.3 8.9 7.2 4.8 5.4 0.09 0.10
SD 0.5 0.2 2.7 1.0 1.0 2.0 0.02 0.03
Table 2 Doxorubicin pharmacokinetic parameters derived from
the model parameters (Table 1) in four non-human primates that
received doxorubicin (2 mg/kg i.v. over 60 min) alone ()CsA) and
doxorubicin (2 mg/kg i.v. over 60 min) with CsA by continuous
infusion over 48 h (+CsA)
Monkey no. Vss (l/kg) AUCplasma (nM á h) Clearance (l/h/kg) t1/2 (h)
)CsA +CsA )CsA +CsA )CsA +CsA )CsA +CsA
R895 74.2 46.7 1928 1444 20.1 13.2 8.2 7.5
D16 126.3 57.2 2182 1693 14.2 8.9 13.8 12.0
B9078 105.3 111.5 2334 1910 15.7 8.7 12.5 17.8
R838 A 84.7 73.4 1963 2004 15.1 7.7 12.1 12.9
Mean 97.6 72.2 2101 1763 16.3 9.6 11.6 12.6
SD 23.1 28.4 191 249 2.6 2.4 2.4 4.2
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chemical staining for these two antibodies showed a
pattern consistent with a transmembrane protein, with
staining in the cytoplasm and on the plasma membrane.
The presence of Pgp on the epithelial surface of the
choroid plexus is further evidence that the ependymal
epithelium is the site of the blood-CSF barrier and that
CSF penetration is a valid surrogate for BBB penetra-
tion for studying the eects of Pgp modulators on the
CNS pharmacology of anticancer drugs.
The higher brain levels of vinblastine in the mdr1a
knockout mouse suggests that blocking Pgp with a
modulating agent such as CsA would result in higher
CNS and CSF concentrations of drugs that are Pgp
substrates. In our non-human primate model, we
achieved CsA blood levels that exceeded concentrations
required to inhibit Pgp in vitro [12, 13, 24] and resulted
in altered doxorubicin pharmacokinetics (42% reduc-
tion in doxorubicin clearance) in the animals. However,
CsA did not significantly increase the CSF penetration
of doxorubicin. Our results are consistent with those of a
study in rodents in which high doses of the Pgp inhibi-
tors, CsA, verapamil, amiodarone, trifluoperazine,
quinidine and Bay K8644, did not increase the perme-
ability of the BBB in mice despite altering pharmaco-
kinetics of the cytotoxic agent in other tissues that
normally express Pgp [25]. In addition, in rats CsA has
no impact on brain levels of etoposide [26].
Preclinical studies using the more potent CsA analog,
PSC833, have demonstrated dose-dependent CNS pen-
etration of the drug, due to a blood concentration-
dependent modulation of the BBB [27]. Clinical studies
using PSC833, are ongoing, and the dose-limiting tox-
icity appears to be neurologic (predominantly ataxia)
[28] but it has not yet been determined whether this is a
direct result of Pgp inhibition or an inherent toxicity of
the PSC833 that is unrelated to its inhibition of Pgp [28].
In our non-human primates, CsA did not enhance
hepatic, renal, neurologic, or hematologic toxicity of
doxorubicin compared to doxorubicin alone, when the
drug exposure (AUC) was kept constant by lowering the
doxorubicin dose in proportion to the reduction in
clearance in the combination regimen.
The potential clinical consequences of eective Pgp
inhibition in normal tissues that express Pgp could in-
clude enhanced chemotherapy-related toxicity due to
impaired clearance of chemotherapeutics that are Pgp
substrates, altered distribution of anticancer drugs with
enhanced access to pharmacologic ‘‘sanctuary’’ sites
such as the CNS and testis, and enhanced hematologic
toxicity from sensitization of Pgp-expressing stem cells
[28]. At the dose of doxorubicin used in this study, we
observed altered doxorubicin clearance, but the CNS
penetration and hematologic toxicity did not appear to
be aected. The concentration of the Pgp-modulating
agent that aects drug clearance may be lower than the
concentration of the modulating agent that is required
to open the BBB, or brain capillary endothelial cells may
have other mechanisms to block drug entry into the
CNS that are independent of Pgp [29–31].
Although CsA did not appear to significantly increase
the CSF penetration of doxorubicin in our animal
model, further studies to quantify the eects of more
potent Pgp modulators on the CNS pharmacology of
doxorubicin and other anticancer drugs that are Pgp
substrates are warranted because of the potential impact
of enhanced CNS penetration on the treatment of CNS
tumors and risk for neurotoxicity.
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